Prostate cancer is the most common malignancy found in males; however, little is as yet known regarding what initiates the disease. The incidence is highest among American Blacks and lowest in the East Asian population. Subtypes of the disease include familial clustering and a hereditary form (9%) supporting genetic events to be involved in prostate cancer pathogenesis. Chromosomal abberations so far identified as being frequently occurring in this disease seem to be related to later phases of disease progression. However, research finding the responsible promoting genetic alteration is rapidly progressing. To explain the varied geographical distribution of the disease, the environment also has to be taken into account. Risk factors identified so far include obesity, animal fat, red meat consumption and certain toxins containing cadmium, while vegetables, cereals and vitamin D seem to be protective. It is reasonable to believe that, in the near future, we will be able to identify persons at risk of acquiring the disease and then inform them how to adjust their lifestyle to avoid early progression of the malignancy.

1.
Woolf CM: An investigation of familial aspects of carcinoma of the prostate. Cancer 1960;13:739–744.
2.
Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR: Genetic epidemiology of prostate cancer in the Utah Mormon Genealogy. Cancer Surv 1982;1:47–69.
3.
Meikle AW, Stanish WM: Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 1982;54:1104–1108.
4.
Meikle AW, Smith JA, West DW: Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 1985;6:121–128.
5.
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of prostate cancer. Prostate 1990;17:337.
6.
Isaacs SD, Kiemeney LALM, Baffoe-Bonnie A, Beaty TH, Walsh PC: Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995;87:13.
7.
Grönberg H, Damber L, Damber JE: Familial prostate cancer Sweden. A nation-wide register cohort study. Cancer 1996;77:138–143.
8.
Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C et al: Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995;154:404–406.
9.
Grönberg H, Damber L, Damber JE: Studies of genetic factors in prostate cancer in a twin population. J Urol 1994;152:1484–1489.
10.
Carter HB, Piantadosi S, Isaacs JT: Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742–746.
11.
Carter BS, Ewing CM, Ward SW et al: Allelic loss of chromosome 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990;87:8751–8755.
12.
Bergerheim USR, Kunimi K, Collins VP et al: Deletion mapping of chromosomes 8, 10 and 16 in human prostatic carcinoma. Genes Chrom Cancer 1991;3:215–220.
13.
Kunimi K, Bergerheim USR, Larsson IL et al: Allelotyping of human prostatic adenocarcinoma. Genomics 1991;11:530–536.
14.
Matsuyama H, Yi P, Yoshihiro S, Häggarth L, Chunde L, Tribukait B et al: Deletion of chromosome 8p22 for the development of disease progression in prostate cancer. Cancer Res, submitted.
15.
Pan Y, Matsuyama H, Naining W, Yoshihiro S, Häggarth L et al: Chromosome 16q24 deletion and decreased E-cadherin expression: Possible association with metastatic potential in prostate cancer. Prostate 1998;36:31–38.
16.
Cher ML, Ito T, Weidner N, Carroll PR et al: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 1995;153:249–254.
17.
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus H et al: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104–5109.
18.
Chunde L, Larsson C, Futreal A, Lancaster J et al: Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogenes 1998;16:481–487.
19.
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367.
20.
Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI: Pathological features of hereditary prostate cancer. J Urol 1995;153:987–992.
21.
Smith JR, Freier D, Carpten J, Grönberg H et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genomic wide search. Science 1996;274:1371–1373.
22.
Eels RA, Durocher F, Edwards S, Teare D et al: Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet 1998;62:633–638.
23.
Barriton P, Valerie A, Kenakenile A, Drellan E et al: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q 42.2-43. Am J Hum Genet 1998;62:1416–1424.
24.
Xu J, Schleutker J, Berry R, Grönberg H, Smith J et al: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175–179.
25.
Hall JM, Lee MK, Newman B, Morow JE, Anderson LA: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684–1689.
26.
Tulinius H, Eglsson V, Olafsdóttir GH, Sigvaldason H: Risk of prostate, ovarial and endometrial cancer among relatives of breast cancer patients. BMJ 1992;305:855–857.
27.
Arason A, Barkardóttir RB, Egilsson V: Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet 1993;52:711–717.
28.
Xiang G, Zacharek A, Salkowski A, Grignon DJ, Sakr W et al: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995;55:1002–1005.
29.
Anderson DE, Badzioch MD: Familial effects of prostate and other cancers on lifetime breast cancer risk. Breast Cancer Res Treat 1993;28:107–113.
30.
Sellers TA, Potter JD, Rich SS, Drinkard CR, Bostick RM: Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994;86:24.
31.
Gao X, Zacharek A, Salkowski A, Grignon DJ, Wael S, Porter AT, Honn KV: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995;55:1002–1005.
32.
Murakami YS, Brothman AR, Leach RJ, White RL: Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 1995;55:3389–3394.
33.
Williams BJ, Jones E, Xiao LZ, Steele MR, Stephenson RA et al: Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 1996;155:720–725.
34.
Haenszel W, Kurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. N Natl Cancer Inst 1968;40:43–68.
35.
Carter HB, Piantadosi S, Isaacs JT: Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742–746.
36.
Watanabe M, Ushijima T, Kaiuchi H, Shiraishi T, Yatani R et al: p53 gene mutations in human prostate cancers in Japan: Different mutations spectra between Japan and Western Countries. Jpn J Cancer Res 1994;85:904–910.
37.
Konishi N, Hiasa Y, Hayashi I, Matsuda H, Tsuzuki T et al: p53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 1995;86:57–63.
38.
Takahashi H, Furusato M, Allsbrook WC Jr, Niishii H, Wakui S et al: Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 1995;55:1621–1624.
39.
Edwards A, Hammond HA, Lin J, Caskey CT, Chakraborty R: Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992;12:241–253.
40.
McLean HE et al: Abnormal androgen receptor binding affinity in subjects with Kennedy’s disease (spinal and bulbar muscular hypertrophy). J Clin Endocrinol Metab 1995;80:508–516.
41.
Irvine RRA et al: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937–1940.
42.
Coetzee GA, Ross RK: Re: Prostate cancer and the androgen receptor. J Natl Cancer Inst 1994;86:872–882.
43.
Ingles SA, Ross RK, Yu NC, Irvine RA et al: Association of prostate cancer risk with genetic polymorphism in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166–170.
44.
Key T: Risk factors for prostate cancer. Cancer Surv 1995;23:63.
45.
Kolonel LN: Nutrition and prostate cancer. Cancer Causes Control 1996;7:83–94.
46.
Morton MS, Griffiths K, Blacklock N: The preventive role of diet in prostatic disease. Br J Urol 1996;77:481–493.
47.
Grönberg H, Damber L, Damber JE: Total food consumption and body mass index in relation to prostate cancer risk: A case-control study in Sweden with prospectively collected exposure data. J Urol 1996;155:969–974.
48.
Clinton SK, Palmer SS, Spriggs CE et al: Growth and Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents. J Nutr 1988;118:908.
49.
Pollard M, Luckert PH: Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats. Prostate 1985;6:1.
50.
Hill P, Wynder EL, Garbaczewski L, Garnes H, Walker ARP: Diet and urinary steroids in black and white North American men and black South African men. Cancer Res 1979;39:5101.
51.
Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y et al: A case-control study of prostatic cancer with reference to dietary habits. Prostate 1988;12:179–190.
52.
Kolonel LN, Hankin JH, Yoshawa CN: Vitamin A and prostate cancer in elderly men: Enhancement of risk. Cancer Res 1987;47:2982–2985.
53.
Kleemola P, Virtanen M, Pietinen P: The 1992 diet survey of Finnish adults, vol B2/1994. Helsinki, Helsinki National Public Health Institute, Department of Nutrition, 1994.
54.
Landström M, Zhang JX, Hallmans G, Åman P et al: Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 1998;36:151–161.
55.
Bylund A, Zhang JX, Bergh A, Damber JE et al: Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Submitted.
56.
Steele R, Lees REM, Kraus AS et al: Sexual factors in the epidemiology of cancer of the prostate. J Chron Dis 1971;24:29–37.
57.
Sitas F: Geographical epidemiology of prostate cancer: Is there an association with infection? Cancer Surv 1995;23:79.
58.
Jackson MA, Ahluwalia BS, Herson J et al: Characterization of prostatic carcinoma among blacks: A continuation report. Cancer Treat Rep 1977;61:167–172.
59.
Zumoff B, Levin J, Strain GW et al: Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a ‘two-disease’ theory. Prostate 1982;3:579–588.
60.
Drafta D, Proca E, Zamfir V et al: Plasma steroid levels in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 1982;17:689–693.
61.
Harper ME, Peeling WB, Cowley T et al: Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol 1976;81:409–426.
62.
Habib FK, Lee IR, Stich SR et al: Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate. J Endocrinol 1976;71:99–107.
63.
Schuman LM, Mandel J, Blackard C et al: Epidemiologic study of prostatic cancer: Preliminary report. Cancer Treat Rep 1977;61:181–186.
64.
Rotkin ID: Studies in the epidemiology of prostatic cancer: Expanded sampling. Cancer Treat Rep 1977;61:173–180.
65.
Krain LS: Some epidemiologic variables in prostatic carcinoma in California. Prev Med 1974;3:154–159.
66.
Rooney C, Beral V, Maconochie N, Fraser P, Davies G: Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority. BMJ 1993;307:1391–1397.
67.
Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 1990;10:1307–1312.
68.
Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality. Cancer 1992;70:2861–2869.
69.
Preece MA, Tomlinson S, Ribot CA, Pietrek J, Korn HT et al: Studies of vitamin D deficiency in man. Q J Med 1975;176:575–589.
70.
Eisman JA, Barkla DH, Tutton PJ: Suppression of in vivo growth of human solid tumor xenografts by 1α,25-dihydroxyvitamin D3. Cancer Res 1987;47:21–25.
71.
Abe M, Miyayra C, Sakagami H et al: Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981;78:4990–4994.
72.
Chida K, Hashiba H, Fukushima M, Suda T, Kuroki T: Inhibition of tumor promotion in mouse skin by 1α,25-dihydroxyvitamin D3. Cancer Res 1985;45:5426–5430.
73.
Reitsma PH, Rothberg PG, Astrin SM et al: Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983;306:4992–4994.
74.
Peehl DM et al: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805–810.
75.
Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M et al: Vitamin D and prostate cancr: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467–472.
76.
Morrison NA et al: Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphism. Proc Natl Acad Sci USA 1992;89:6665–6669.
77.
Kovi J, Heshmat MY: Incidence of cancer in Negroes in Washington, DC, and selected African cities. Am J Epidemiol 1972;96:401–413.
78.
M’Buyamba-Kabangu JRM, Fagard R, Lijnen P, Bouillon R, Lissens W, Amery A: Calcium, vitamin D-endocrine system, and parathyroid hormone in black and white males. Calcif Tissue Int 1987;41:70–74.
79.
Morrison H, Savitz D, Semenciw R, Hulka B, Yang M et al: Farming and prostate cancer mortality. Am J Epidemiol 1993;137:270–280.
80.
Wiklund K, Dich J: Cancer risks among male farmers in Sweden. Eur J Cancer Prev 1995;4:81–90.
81.
Dich J, Wiklund K: Prostate cancer in pesticide applicators in Swedish agriculture. Prostate 1998;34:100–112.
82.
Piscator M: Role of cadmium in carcinogenesis with special reference to cancer of the prostate. Environ Health Perspect 1981;40:107–120.
83.
Larsson SE, Lorentzon T: The effect of cadmium exposure on vitamin D metabolism; in Norman A (ed): Vitamin D and Problems Related to Uremic Bone Disease. Berlin, de Gruyter, 1975, pp 67–73.
84.
Waalkes MP, Rehm S: Cadmium and prostate cancer. J Toxicol Environ Health 1994;43:251–269.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.